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BACKGROUND: Opioids are frequently prescribed for moderate to
severe pain. A side effect of opioid usage is the inhibition of gastroin-
testinal (GI) motility, known as opioid-induced bowel dysfunction
(OBD). OBD is typically treated prophylactically with laxatives
and/or acid suppressants.
AIM: The present study describes the prevalence of outpatient opi-
oid dispensing, opioid patient demographics, and concomitant dis-
pensing of opioids and GI medications in the Quebec Public
Prescription Drug Insurance Plan in 2005.
METHODS: Using a retrospective cohort design, opioid dispensings
were identified using claims and reimbursement data. Laxative and
acid suppressant dispensings were also identified. Concurrent use was
defined as having at least one ‘GI medication-exposed day’ overlap-
ping an ‘opioid-exposed day’.
RESULTS: More than 11% of the drug plan population was dis-
pensed an opioid in 2005, and dispensings increased with age.
Approximately two-thirds of patients who received an opioid were
given codeine. Approximately one-third of opioid patients were con-
comitantly dispensed a GI medication, yet only 2% were dispensed a
laxative.
CONCLUSIONS: Although the GI side effects of opioids are well
known, these side effects appear to increase with age and duration of
opioid use. Opioid-related side effects, particularly OBD, should be
effectively managed so as not to lead to the cessation of opioid therapy.
Key Words: Dispensings; Epidemiology; Laxative; Opioid;
Prevalence; Upper GI medication
Prévalence de l’utilisation concomitante d’opi-
acés et de médicaments GI au Québec
HISTORIQUE : On prescrit souvent des opiacés pour la douleur de
modérée à sévère. L’un des effets secondaires des opiacés est l’inhibition
de la motilité gastro-intestinale (GI), connue sous le nom de dysfonction
intestinale induite par les opiacés (DIO). La DIO est en général traitée de
manière prophylactique au moyen de laxatifs et/ou de suppresseurs de
l’acidité.
OBJECTIF : La présente étude décrit la prévalence des ordonnances
d’opiacés chez les patients non hospitalisés, les caractéristiques démo-
graphiques des patients sous opiacés et l’emploi concomitant d’opiacés et
de médicaments GI selon les données du régime public d’assurance-
médicaments du Québec pour 2005.
MÉTHODE : À partir d’un modèle de cohorte rétrospective, on a recen-
sé les opiacés servis à partir des données de réclamations et de rembourse-
ments. On a également recensé les laxatifs et les suppresseurs de l’acidité
servis. L’utilisation concomitante était définie par l’emploi le même jour
d’au moins un médicament GI et d’un opiacé.
RÉSULTATS : Plus de 11 % de la population qui bénéficie du régime
d’assurance-médicaments a reçu une ordonnance d’opiacés en 2005 et la
proportion augmentait avec l’âge. Il s’agissait de codéine chez près des
deux tiers des patients sous opiacés. Environ un tiers des patients sous opi-
acés prenait concomitamment un médicament GI et pourtant, 2 % seule-
ment ont reçu un laxatif.
CONCLUSION : Bien que les effets secondaires GI des opiacés soient
bien connus, ils semblent plus prévalents avec l’âge et la durée du traite-
ment opiacé. Il faut traiter efficacement les effets secondaires liés aux opi-
acés, particulièrement la DIO, pour ne pas entraîner l’arrêt du traitement
par opiacé.
Opioids are common treatments for patients with moderateto severe pain (1-3); however, pain management can be
compromised by the adverse effects of opioid treatment, includ-
ing inhibition of gastrointestinal (GI) motility (4-6). Opiates
induce a delay in gastric emptying, which may lead to nausea
and vomiting, and also slow intestinal and colonic transit,
which may lead to constipation (7-11). Taken together, these
inhibitory effects on GI motility are termed opioid-induced
bowel dysfunction (OBD) and represent an important, and
often dose-limiting, side-effect profile of opioid treatment.
Although large, population-based, prospective studies of
OBD are lacking, estimates of the prevalence of opioid-
induced constipation range from approximately 15% to 50% in
nonmalignant pain patients (12,13) and 25% to 90% in cancer
patients (14,15). Patients with continuing opioid therapy do
not develop a tolerance to constipation, such as they may for
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other opioid-induced side effects such as nausea and vomiting
(16,17). In an attempt to avoid constipation, patients may
reduce their opioid level or frequency of use, or they may dis-
continue opioid therapy altogether. Hence, in an effort to
reduce constipation, effective pain management may be com-
promised (2,18).
Prophylactic treatment for the constipating aspects of OBD
is often recommended at the start of opioid therapy, especially
in patients who need to use opioids chronically, such as termi-
nally ill cancer patients (14,19). Treatment of constipation
typically includes laxatives and/or stool softeners; however,
these therapies are often insufficient, and higher or more fre-
quent doses may be required as the duration of opioid use
increases (20,21). Constipation and its sequelae may signifi-
cantly reduce a patient’s quality of life, lead to increased med-
ical costs or lead to termination of needed pain medications.
Despite widespread recognition of OBD, the epidemiology
of concomitant opioid use with laxatives or medications affect-
ing the upper GI tract is poorly described. The objectives of
our study were to describe the prevalence of outpatient opioid
dispensing in the Quebec Public Prescription Drug Insurance
Plan in 2005; describe the age and sex of the patients receiving
opioids; gain a better understanding of the population that has
chronic and long-term chronic opioid dispensings; assess the
type of opioids being dispensed; and evaluate the concomitant
dispensing of over-the-counter and prescription laxatives
and/or upper GI medications in opioid users. 
METHODS
Quebec Public Prescription Drug Insurance Plan
There are approximately eight million people residing in
Quebec, Canada’s second most populous province. This
accounts for over 23% of the Canadian population. The source
population for the present analysis includes enrollees covered
under the Quebec Public Prescription Drug Insurance Plan.
This program is set up to provide services for citizens who do not
have private group insurance and is administered by La Régie de
l’assurance maladie du Québec. All residents of Quebec, regardless
of their financial situation, are eligible for enrollment in this
government-based, universal health care plan; however, the
plan is intended to enroll the following groups: those without
a private health care plan; children of people covered by this
public plan; people 65 years of age and older; and welfare recip-
ients. In total, this drug prescription plan covers approximately
3.2 million of the eight million residents of the province. 
The formulary for the Quebec Public Prescription Drug
Insurance Plan registers more than 4500 over-the-counter and
prescription drugs. Because the majority of the population in
Quebec uses the public plan to obtain medications, this cohort
can be considered generally representative of the larger
Quebec population, excluding those residents with private
insurance. 
Study population
The present study design is a retrospective cohort design,
with the analyses conducted at the personal level, using peo-
ple as the unit of measurement. The study period was defined
as January 1, 2005 to December 31, 2005. The inclusion cri-
teria were designed to enroll adults with a full year of cover-
age in the Quebec Public Prescription Drug Insurance Plan.
These criteria included people in the Quebec Public
Prescription Drug Insurance Plan who were 18 years of age or
older at the start of the study period; eligible for drug benefits
for the entire study period; did not die before the end of the
study period; and had at least one opioid dispensing between
January 1, 2005, and December 31, 2005. Once all eligible
patients were identified using the inclusion and exclusion cri-
teria, a random sample of 25% of the patients was received, as
per government guidelines.
Opioid dispensings
Opioid dispensings were identified by examining the claims
data for opioids that were reimbursed by the Quebec Public
Prescription Drug Insurance Plan. Opioids administered orally,
by transdermal patch, rectal suppository and nasal spray were
included. This included butorphanol tartrate, codeine
(codeine phosphate, codeine phosphate with acetaminophen,
codeine with codeine sulfate), fentanyl, hydromorphone HCl,
meperidine HCl, morphine (morphine HCl, morphine sul-
fate), oxycodone (oxycodone HCl, oxycodone with acetamin-
ophen), pentazocine and sufentanil citrate. 
Due to the nature of the data, all opioid dispensings were to
outpatients; data on use of opioids by hospital inpatients were
not available in the present study. It is understood that the
data reflect no particular legal restriction on the units of opioid
medication that may be dispensed. Physicians may prescribe
more frequent, shorter-term dispensings rather than less fre-
quent, longer-term dispensings. The data available for each
dispensing were as follows: drug name, date of dispensing,
number of days supplied, number of units dispensed and
strength of units dispensed. To determine the specific days of
intended opioid use, the date of dispensing was identified and
the number of days supplied for each opioid dispensing. From
this information, ‘opioid-exposed days’ were defined as all
dates beginning with the date of dispensing through the end of
the number of days supplied. 
Chronic use definitions
‘Chronic opioid use’ was defined a priori as 60 or more consec-
utive opioid-exposed days, with no more than seven consecu-
tive days between the end of one dispensing and the start of
the next dispensing. This gap in opioid-exposed days was
allowed because patients do not always get their prescriptions
filled on time and opioid use maybe adjusted to meet their pain
needs, making an opioid prescription last longer than pre-
scribed. From this definition, ‘chronic users’ were defined as
people with at least one period of chronic opioid use in 2005. 
A subset of the chronic users, ‘long-term chronic users’ were
also defined a priori; these people met the definition of a
chronic user and had at least 180 consecutive opioid-exposed
days, with no more than seven consecutive days between the
end of one dispensing and the start of the next dispensing. 
‘Nonchronic users’ were defined a priori as people with an
opioid dispensing that did not meet the definition for chronic
use during the study period. Hence, nonchronic users had 59 or
fewer consecutive opioid-exposed days. Having seven days or
less between opioid dispensings was considered consecutive as
described above; eight or more days between opioid dispensings
was considered a new period of use, and hence, not consecutive.
During the course of the one-year study period, a person
may have periods of chronic opioid use and other periods of
nonchronic opioid use. For these analyses, people with any
chronic opioid use during the study period were considered
chronic users for all analyses. A person was considered a
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nonchronic user if all opioid dispensings were nonchronic
(59 or fewer consecutive opioid-exposed days). Furthermore, a
person with any chronic opioid use did not meet the study
definition of a nonchronic user in 2005. This decision ensured
mutually exclusive groups, allowed comparisons between peo-
ple with and without any chronic opioid use and aided in the
understanding of study results.
Concurrent laxative and/or acid suppressants
All dispensings of over-the-counter and prescription laxatives
and agents that reduce gastric acid secretion were identified in
the study population. Laxatives included bulk laxatives (planta-
go seed, psyllium hydrophilic muciloid), emollient laxatives
(docusate calcium, docusate sodium, mineral oil), osmotic laxa-
tives (glycerin, lactulose, magnesium hydroxide, sodium citrate
with sodium lauryl sulfoacetate, sodium phosphate monobasic
with sodium phosphate dibasic, and carbowax with sodium sul-
fate, sodium bicarbonate, sodium chloride and potassium chlo-
ride) and stimulant laxatives (bisacodyl, cascara sagrada, cascara
sagrada with magnesium hydroxide, sennosides, sennosides with
docusate sodium). Acid suppressants included proton pump
inhibitors (esomeprazole magnesium trihydrate, lansoprazole,
omeprazole magnesium, pantoprazole, rabeprazole sodium) and
histamine H2 receptor antagonists (cimetidine, cimetidine
hydrochloride, famotidine, nizatidine, ranitidine HCl).
Antacids and absorbents were not included in the present study
because they may be used in the population for reasons unre-
lated to a GI symptom (ie, antacids as a calcium supplement).
‘Laxative-exposed days’ and ‘acid suppressant-exposed days’
were calculated with the same methodology used for ‘opioid-
exposed days.’ These periods included the number of days
between the dispensing date of the laxative and/or acid sup-
pressant through the last day supplied for each agent. Use of
concurrent laxative medication was defined as having at least
one laxative-exposed day that overlapped with an opioid-
exposed day. Use of concurrent acid suppressants was defined
as having at least one acid suppressant-exposed day that over-
lapped with an opioid-exposed day. 
Analyses
Descriptive analyses were conducted to meet each of the
objectives. The prevalence of opioid use was defined as the
number of patients in the Quebec Public Prescription Drug
Insurance Plan database with at least one opioid dispensing
divided by the number of eligible patients enrolled in the pre-
scription drug plan, according to the study inclusion criteria.
All remaining analyses focused on the population of inter-
est – people with at least one opioid dispensing during 2005.
Using this study population as the denominator, sex, age,
chronicity of use, type of opioid used, and concurrent use of
laxatives and/or acid suppressants were described. Data from
the Quebec Public Prescription Drug Insurance Plan were ana-
lyzed using SAS version 9.1 (SAS Institute Inc, USA).
RESULTS
Prevalence of opioid use in Quebec
In the random sample of 25% of all eligible patients, 11.3%
of the population in the Quebec Public Prescription Drug
Insurance Plan were dispensed an opioid in 2005. Based on
an estimated 2,670,338 people in the eligible population, this
proportion (11.3%) may be extrapolated to an estimated
300,660 people in Quebec who were dispensed an opioid in
2005. In the general population, a greater proportion of
women (12.6%) were dispensed opioids than men (9.6%). The
use of opioids increased with age in both sexes until approxi-
mately 80 years of age (Figure 1). Peak prevalence of use
(14.8%) occurred in the 70- to 74-year-old group. 
Characteristics of people with opioid dispensings
Of the 75,165 people in the study population who had received
an opioid dispensing, 61.0% were women (n=45,888) and
39.0% were men (n=29,277) (Table 1). Most patients receiving
an opioid were given codeine (65.7%), followed by hydromor-
phone HCl (25.0%), oxycodone (11.4%) and morphine
(8.1%). The same pattern and similar percentages were found
between men and women. 
Chronic opioid use 
Three categories of patients were defined a priori based on
their opioid dispensings: chronic opioid users, long-term
chronic opioid users and nonchronic opioid users. Using these
categories, 12.4% of patients who received opioids were chronic
users and 87.6% were nonchronic users (Table 1).
Furthermore, a similar percentage of men and women were
chronic (12.2% and 12.5%, respectively) and nonchronic
users (87.8% and 87.5%, respectively). Approximately one-
half of the chronic users (6.4% of the 12.4%) were long-term
chronic users; the percentage of men and women in this cate-
gory was similar (6.5% and 6.3%, respectively). 
The type of opioid prescribed differed among nonchronic,
chronic and long-term chronic users (Table 2). Codeine was
dispensed to 69.6% of nonchronic users, followed by hydro-
morphone HCl (23.3%); all other types of opioids were dis-
pensed to less than 10% of nonchronic users. Among chronic
users, codeine was dispensed to 38.4%, followed closely by
hydromorphone HCl (37.1%), oxycodone (27.2%), fentanyl
(22.3%) and morphine (16.2%). In long-term chronic opioid
users, percentages were similar to those in chronic users,
although codeine was dispensed less frequently (29.9%) and
methadone was dispensed more frequently (11.7%). 
Concurrent laxative and/or acid suppressants
Approximately one-third of people (30.5%) with an opioid
dispensing were concomitantly dispensed a laxative or acid
suppressant medication. Furthermore, slightly more women
Opioids and concurrent GI medications in Quebec







































Figure 1) Prevalence of opioid use in Quebec in 2005 using the
Quebec Public Prescription Drug Insurance Plan database
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(31.9%) than men (28.3%) received a concurrent dispensing
of opioids, and a laxative or acid suppressant (Table 3). When
patients were examined by age group, a substantial difference
in concomitant dispensings of opioids and a laxative or acid
suppressant was observed; 23.5% of patients younger than
65 years of age were concurrently dispensed an opioid and a
laxative or acid suppressant medication compared with 39.5%
of patients 65 years of age and older. The dispensing of con-
comitant laxative or acid suppressant medications increased as
patients were dispensed opioids for extended periods of time;
concurrent dispensings of laxative or acid suppressant medica-
tions was observed in 26.1% of nonchronic opioid users, 59.9%
of chronic users and 62.7% of long-term chronic users. 
Slightly more than 2% of people with an opioid dispensing
had a laxative dispensed concurrently (Table 3), and the per-
centage of men and women in this category was similar (2.4%
and 1.9%, respectively). There were more emollient laxatives
(1.8%) and stimulants (1.5%) concomitantly dispensed with
an opioid than osmotic laxatives (0.4%). Furthermore, people
65 years of age or older had slightly more concomitant opioid
and laxative dispensings than those younger than 65 years of
age (2.6% versus 1.8%). More concomitant laxatives were dis-
pensed among chronic users (11.3%) and long-term chronic
users (15.2%) than nonchronic users (0.8%). The nonchronic
users may serve as a surrogate upper bound for patients not pre-
scribed opioids; therefore, the dispensing of laxatives in
patients who are also dispensed opioids can be assumed to be at
least 10-fold greater than nonopioid users. Among the long-
term chronic users, slightly more women (16.8%) than men
(12.7%) had concomitant laxative dispensings, and almost all
of the laxatives used were dispensed over the counter.
Nearly one-third (29.8%) of patients with an opioid dis-
pensing had a concurrent acid suppressant dispensed (Table 3),
and more women than men received a concurrent dispensing
of opioids and acid suppressants (31.2% and 27.6%, respec-
tively). Twice as many chronic (56.6%) and long-term
(58.5%) opioid users had concomitant acid suppressant treat-
ments dispensed when compared with nonchronic opioid users
(25.7%). Assuming nonchronic users constitute an upper
bound for nonopioid users, those with chronic opioid dispens-
ings were dispensed acid suppressants at least twice as often as
those with nonchronic opioid dispensings. 
DISCUSSION
The results of the present study confirm that a substantial pro-
portion of patients in the Quebec Public Prescription Drug
Insurance Plan received an opioid dispensing in 2005.
Additionally, the proportion of subjects who were dispensed
opioids increased with age, and many of the patients were con-
currently dispensed a laxative or acid suppressant medication. 
Interestingly, approximately two-thirds of patients dis-
pensed an opioid received codeine. In comparison, a Canadian
survey on chronic pain and prevalence of opioid use found that
16.9% (n=340) of 2012 respondents were taking prescription
analgesic medication. Among individuals surveyed with
chronic pain who were taking a prescription analgesic medica-
tion (n=340), 22.6% (n=77) used an opioid and 67.5% (n=52)
of the opioid users reported taking codeine (22). Hence, the
data in the Quebec plan and the survey of chronic pain
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TABLE 1
Characteristics of the study population of people in the
Quebec Public Prescription Drug Insurance Plan with an
opioid dispensed in 2005
Men Women Total
(n=29,277) (n=45,888) (n=75,165)
n (%) n (%) n (%)
Age, years*
18–24 890 (3.0) 2680 (5.8) 3570 (4.7)
25–29 937 (3.2) 2216 (4.8) 3153 (4.2)
30–34 1162 (4.0) 2015 (4.4) 3177 (4.2)
35–39 1553 (5.3) 2256 (4.9) 3809 (5.1)
40–44 2097 (7.2) 2863 (6.2) 4960 (6.6)
45–49 2351 (8.0) 2833 (6.2) 5184 (6.9)
50–54 2261 (7.7) 3110 (6.8) 5371 (7.1)
55–59 2524 (8.6) 3629 (7.9) 6153 (8.2)
60–64 2731 (9.3) 4360 (9.5) 7091 (9.4)
65–69 3983 (13.6) 4997 (10.9) 8980 (11.9)
70–74 3868 (13.2) 5122 (11.2) 8990 (12.0)
75–79 2739 (9.4) 4503 (9.8) 7242 (9.6)
≥80 2181 (7.4) 5304 (11.6) 7485 (10.0)
Chronicity of use
Nonchronic, <60 days 25,709 (87.8) 40,142 (87.5) 65,851 (87.6)
Chronic, ≥60 days 3568 (12.2) 5746 (12.5) 9314 (12.4)
Long-term chronic, 1911 (6.5) 2876 (6.3) 4787 (6.4)
≥180 days
Type of opioid
Codeine 18,961 (64.8) 30,455 (66.4) 49,416 (65.7)
Hydromorphone HCl 7853 (26.8) 10,939 (23.8) 18,792 (25.0)
Oxycodone 3317 (11.3) 5242 (11.4) 8559 (11.4)
Morphine 2300 (7.9) 3756 (8.2) 6056 (8.1)
Fentanyl 898 (3.1) 1890 (4.1) 2788 (3.7)
Meperidine HCl 839 (2.9) 1728 (3.8) 2567 (3.4)
Methadone 451 (1.5) 310 (0.7) 761 (1.0)
Pentazocine 55 (0.2) 135 (0.3) 190 (0.3)
Butorphanol tartrate <6 (<0.1)† 19 (<0.1) <6 (<0.1)†
Sufentanil citrate 0 (0.0) <6 (<0.1)† <6 (<0.1)†
*Age at January 1, 2005; †When a data entry is between 1 and 5 patients, the
exact number is not provided to ensure patient confidentiality; therefore, the
data are reported as <6
TABLE 2
Type of opioid dispensed among participants of the
Quebec Public Prescription Drug Insurance Plan,




Type of opioid % % %
Codeine 69.6 38.4 29.9
Hydromorphone HCl 23.3 37.1 35.3
Oxycodone 9.2 27.2 27.7
Morphine 6.9 16.2 17.1
Fentanyl 1.1 22.3 24.0
Meperidine HCl 3.4 3.6 2.9
Methadone 0.1 7.3 11.7
Pentazocine 0.2 0.6 0.8
Butorphanol tartrate <0.1* <0.1* <0.1*
Sufentanil citrate 0.0 <0.1* <0.1*
*The exact numbers between 1 and 5 are not presented in a data entry to pro-
tect patient confidentiality; therefore, the data are reported as <0.1%
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patients found similar results, with approximately two-thirds of
opioid users taking codeine.
Also, although 30.5% of people who were dispensed an opi-
oid were also dispensed a laxative or acid suppressant, only
2.2% were dispensed a laxative concomitantly. This may be
due in part to underuse of laxatives for opioid-induced consti-
pation, and/or the way laxatives are reimbursed in this system.
The constipating effects of opioid are well known (12-15);
hence, treatment is important to not compromise pain man-
agement. One study showed that 41% of patients receiving a
mean dose of morphine 83 mg/day reported constipation as a
side effect even though they were taking a bowel regimen (23). 
Also, the reimbursement for laxatives differs by drug plans;
hence, some patients may pay out-of-pocket for laxatives that
do not show up in the drug plan data. Further investigation
into the cost per laxative claim revealed that five of the top
10 most frequently prescribed laxatives in the Ontario Drug
Benefit Plan have an average cost per claim reimbursement of
more than $12. Conversely, only one of the 10 most frequently
prescribed laxatives in the Quebec Public Prescription Drug
Insurance Plan has a cost per claim reimbursement of approxi-
mately $12; nearly 80% of the 10 most frequently prescribed
laxatives in the Quebec plan have an average cost or claim
reimbursement of $2. Therefore, differences between over-the-
counter laxative information obtained from various health
plans in Canada may be partially due to differences in filing for
reimbursement rather than true differences in the use between
the populations.
The gastrointestinal side effects of opioids are well known,
and the present study illustrates that these side effects may
increase with age and duration of opioid use. As anticipated,
the chronic and long-term chronic opioid users had greater
concomitant dispensing of GI medications than nonchronic
users; laxatives were dispensed at least 10 times more frequently
and acid suppressants at least twice as frequently in chronic
opioid users than nonchronic opioid users. We believe the
nonchronic users may represent an upper bound for the non-
opioid users. Because the older population is more likely to
have comorbidities and reduced GI functioning, any potential
opioid-related side effects may have a greater impact.
Therefore, greater focus on pain management and appropriate
treatment of associated side effects may be especially important
for this population because it is critical that opioid-induced
side effects do not lead to cessation of the necessary opioid
therapy.
There are several limitations of the present study due to the
use of a prescription drug plan database. Although we have
actual dispensings of medications, we do not have prescrip-
tions or patient-reported data. Therefore, we cannot account
for possible differences between the dispensing data and the
instructions given by the physician, or the actual medication use
by the patient. When opioids are prescribed on an as-needed
basis, the pharmacist has to make the assumption that the
number of units per day divided by total number of units equals
the number of days supplied; therefore, the number of days sup-
plied may be an underestimate or overestimate of the actual
number of days a medication was used. We also do not know if
the concomitant GI medications were prescribed due to side
effects of the opioid or for other reasons. Considering the large
differences between chronic and nonchronic opioid users in
both concurrent laxative and acid suppressant use, it is likely
that these GI treatments were in response to opioid-related
side effects. 
Despite these limitations, there are several strengths to this
database analysis study. This drug plan is likely representative
of approximately 3.2 million residents of Quebec. All drug dis-
pensings must be prescribed by a physician, even if the med-
ications can be bought over the counter. Drugs are identified
by the Canadian Drug Identification Number, which signifies a
unique combination of chemical entity, trade name, strength
and form. Unlike insurance claims data in the United States,
the database used in the present study contains information on
over-the-counter medications, which is essential when evalu-
ating laxative and acid suppressant use. Lastly, due to the large
sample size available, we were able to identify concomitant
medications that were used in only a small percentage of the
population. 
CONCLUSION
Opioids represent a frequently dispensed medication.
Associated with their use is an increase in concomitant med-
ications to treat OBD; in particular, laxatives and acid suppres-
sant therapies. The use of these medications is essential
because, for some patients, cessation of opioid therapy has
negative and dramatic consequences due to the requirement of
analgesia to relieve their pain. 
Opioids and concurrent GI medications in Quebec
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TABLE 3
Concurrent dispensings of laxative and/or acid suppressant therapies with opioids by sex in the Quebec Public
Prescription Drug Insurance Plan in 2005
Men Women <65 years old ≥65 years old Nonchronic Chronic Long-term chronic Total
(n=29,277) (n=45,888) (n=42,468) (n=32,697) (n=65,851) (n=9314) (n=4787) (n=75,165)
% % % % % % % %
Laxatives 1.9 2.4 1.8 2.6 0.8 11.3 15.2 2.2
OTC 1.9 2.3 1.8 2.6 0.8 11.2 14.9 2.2
Prescription <0.1* <0.1* <0.1* <0.1* <0.1* <0.1* <0.1* <0.1*
Acid suppressant therapies 27.6 31.2 23.0 38.7 25.7 56.6 58.5 29.8
OTC <0.1* <0.1* 0.0 <0.1* <0.1* <0.1* 0.0 <0.1*
Prescription 27.6 31.2 23.0 38.7 25.7 56.6 58.5 29.8
Laxatives or acid 28.3 31.9 23.5 39.5 26.1 59.9 62.7 30.5
suppressant therapies†
*The exact numbers between 1 and 5 in a data entry are not presented to protect patient confidentiality; therefore, the data are presented as <0.1%; †All types of
laxative. Acid suppressant therapies include proton pump inhibitors and histamine H2 receptor antagonists. OTC Over-the-counter
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